Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms.
Arribas AJ, Napoli S, Cascione L, Barnabei L, Sartori G, Cannas E, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, de Moura MC, Jovic S, Pittau RB, Stathis A, Stussi G, Gattei V, Brown JR, Esteller M, Zucca E, Rossi D, Bertoni F. Arribas AJ, et al. Among authors: pittau rb. bioRxiv [Preprint]. 2023 Jan 2:2023.01.01.522017. doi: 10.1101/2023.01.01.522017. bioRxiv. 2023. Update in: Mol Cancer Ther. 2024 Mar 4;23(3):368-380. doi: 10.1158/1535-7163.MCT-23-0068. PMID: 36711490 Free PMC article. Updated. Preprint.
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.
Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi D, Stathis A, Stussi G, Broggini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F. Tarantelli C, et al. Among authors: pittau rb. Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24. Clin Cancer Res. 2018. PMID: 29066507
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Arribas AJ, Guidetti F, Cannas E, Cascione L, Napoli S, Sartori G, Fuzio F, Pesenti E, Tarantelli C, Spriano F, Zucchetto A, Rossi FM, Bruscaggin A, Rinaldi A, Castro de Moura M, Jovic S, Raimondi A, Pittau RB, Terzi di Bergamo L, Ye X, Stathis A, Ben-David Y, Pan-Hammarström Q, Simonetta F, Stussi G, Zucca E, Gattei V, Brown JR, Esteller M, Rossi D, Bertoni F. Arribas AJ, et al. Among authors: pittau rb. bioRxiv [Preprint]. 2025 May 10:2025.05.07.652612. doi: 10.1101/2025.05.07.652612. bioRxiv. 2025. PMID: 40654846 Free PMC article. Preprint.